MARKET

ABEO

ABEO

Abeona
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.990
-0.110
-5.24%
Closed 19:21 04/01 EDT
OPEN
2.000
PREV CLOSE
2.100
HIGH
2.350
LOW
1.900
VOLUME
2.77M
TURNOVER
--
52 WEEK HIGH
8.41
52 WEEK LOW
1.350
MARKET CAP
166.41M
P/E (TTM)
-1.3047
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ABEO stock price target is 9.86 with a high estimate of 17.00 and a low estimate of 4.000.

EPS

ABEO News

More
  • Regenxbio: A Growth Stock For The Coronavirus Bear Market
  • Seeking Alpha - Article · 1d ago
  • Edited Transcript of ABEO earnings conference call or presentation 17-Mar-20 2:00pm GMT
  • Thomson Reuters StreetEvents · 1d ago
  • Penny Stocks to Buy Using Technical Analysis for April 2020
  • Investopedia · 1d ago
  • RenovaCare's SkinGun used in RDEB gene therapy study
  • Seeking Alpha - Article · 2d ago

Industry

Biotechnology & Medical Research
-4.52%
Pharmaceuticals & Medical Research
-2.91%

Hot Stocks

Symbol
Price
%Change

About ABEO

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa, ABO-301 (AAV-FANCC) for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. The Company also has a plasma-based protein therapy pipeline, including alpha-1 protease inhibitor (SDF Alpha) for inherited COPD, using its proprietary Salt Diafiltration ethanol-free process.
More

Webull offers kinds of Abeona Therapeutics Inc stock information, including NASDAQ:ABEO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABEO stock news, and many more online research tools to help you make informed decisions.